Previous 10 | Next 10 |
Blueprint Medicines Corporation (BPMC) Q1 2020 Earnings Conference Call May 6, 2020, 08:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chief Commercial Officer Mike Landsittel - CFO Andy Boral - Chief Medical Officer Con...
Blueprint Medicines (NASDAQ: BPMC ): Q1 GAAP EPS of -$2.11 beats by $0.05 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , May 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the first qua...
Aurinia Pharmaceuticals (AUP CN) initiated with Outperform rating and C$30 (29% upside) price target at Cowen and Company. No premarket activity yet (NASDAQ: AUPH ) in U.S. More news on: Aurinia Pharmaceuticals Inc., Blueprint Medicines Corporation, Cytokinetics, Incorporated, Healthcare s...
CAMBRIDGE, Mass. , April 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ...
Gainers: Creative Realities (NASDAQ: CREX ) +125% . More news on: Creative Realities, Inc., Syndax Pharmaceuticals, Inc., Kura Oncology, Inc., Stocks on the move, , Read more ...
Shares of Blueprint Medicines (NASDAQ: BPMC) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal stromal tumors (GIST). The experimental therapy didn't lead to an improvement in progression-free...
NeuBase Therapeutics (NASDAQ: NBSE ) -15% on equity offering . More news on: NeuBase Therapeutics, Inc., Yield10 Bioscience, Inc., Blueprint Medicines Corporation, Stocks on the move, , Read more ...
Blueprint Medicines (NASDAQ: BPMC ) slumps 15% premarket in reaction to its announcement that a Phase 3 clinical trial, VOYAGER , evaluating lead candidate avapritinib, branded as Ayvakit, in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) failed to...
CAMBRIDGE, Mass. , April 28, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced top-line results from the Phase 3 VOYAGER clinical trial of avaprit...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...